ECE2020 Audio ePoster Presentations Diabetes, Obesity, Metabolism and Nutrition (285 abstracts)
Effects of semaglutide on glycemic control and body composition in patients with type 2 diabetes mellitus and obesity in a real life setting in spain
Bogdana luiza luca 1 , Roberto Miguel Sierra Poyatos 1 , Jersy Cardenas 1 , Nancy Sanchez Gomez 1 , Maria Jesus Silva Rodriguez 1 , Naiara Modroño Mostoles 1 , Teresa Montoya Alvarez 1 , Raquel Sanchez Lopez 1 , Eva Cruces Vega 2 , Alicia Estrella 1 , Pilar Barrio 1 , Begoña Sanchez Lechuga 1 , Irene Gonzalo Montesinos 1 , Maria Jose De la Cruz Fernandez 1 , Enrique Perez Alvarez 1 & Clotilde Vazquez Martinez 1
1Hospital Universitario Fundacion Jimenez Diaz, Endocrinology, Madrid, Spain; 2Hospital Universitario Infanta Elena, Valdemoro, Spain
Introduction: Semaglutide is a GLP1 receptor agonist (GLP1RA) recently approved in Spain for the treatment of Type 2 Diabetes (T2D) and the National Health Service finances it for patients with T2D and body mass index (BMI) > 30 with a poor metabolic control with metformin.
Objectives: Evaluate the effects of Semaglutide on glycemic control and body composition in patients with T2D (PwT2D) and obesity after 6 months of use in a real life setting.
Material and Methods: This is a retrospective observational study. We included PwT2D and obesity without prior treatment with GLP1RA, who started semaglutide treatment (added to other antidiabetic drugs) between May 2019 and July 2019 in our clinic and maintained it for at least 6 months. Anthropometric measurements (including body composition when available – estimated with bioimpedance Inbody270), fasting glucose (FG) and glycated hemoglobin (HbA1c) were collected at baseline and at 6 months. Statistical analysis was performed with STATA 14. Paired T-student test for comparison between baseline and 6 months and logistic regression to evaluate Semaglutide dose (≤ 0.5 and 1.0 mg), age, sex, duration of T2DM, BMI and HbA1c at baseline as possible predictors of Semaglutide efficacy to achieve HbA1c < 7%.
Results: We included 75 patients (62% men), with a mean age of 62.3 ± 9.2 years and a mean duration of T2D of 11.3 ± 7.4 years. The maximum weekly dose of semaglutide used were: 0.25 mg (2.7%), 0.5 mg (85.3%), 1 mg (12%). After 6 months of treatment, there was significant improvement of glycemic control: HbA1c decreased from 8.08 ± 1.52% to 6.68 ± –1.07 (mean difference –1.39%; P = 0.000) and FG from 169.4 ± 55.9 to 131.5 ± 38,2 mg/dl (mean difference –37.9; P = 0.000). 28% of patients had a HbA1c < 7% in the beginning and 63% after 6 months of treatment with semaglutide. Baseline HbA1C was an independent predictor to achieve HbA1c < 7% 6 months after starting Semaglutide (OR 0,5; CI95% 0.31 to 0.81).
Table 1 shows the changes in anthropometric measurements.
| Baseline | 6 months after (mean difference) | P | |
| Body weight (kg) | 99.46 ± 18.87 | 94.11 ± 18.09 (–5.34) | 0.000 |
| BMI (kg/m2) | 36.14 ± 5.96 | 34.19 ± 5.5 (–1.95) | 0.000 |
| Waist circumference (cm) | 118.2 ± 12.95 | 111.98 ± 14.36 (–6.22) | 0.000 |
| Fat mass (%) | 42.46 ± 7.65 | 40.8 ± 8.5 (–1.58) | 0.162 |
| Muscle mass (kg) | 30.65 ± 7.36 | 29.74 ± 6.12 (–0.91) | 0.385 |
Conclusions: PwT2D in our clinic treated with Semaglutide (mostly 0.5 mg/week) for 6 months had a significant decrease in HbA1c, FG, body weight and waist circumference. The percentage of patients with HbA1c < 7% almost doubled.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more